Bausch Health Companies Inc. (TSX:BHC)

Bausch Health Companies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	10,266	9,625	8,757	8,124	8,434
Revenue Growth (YoY)	6.66%	9.91%	7.79%	-3.68%	5.07%
Cost of Revenue	3,013	2,782	2,559	2,364	2,394
Gross Profit	7,253	6,843	6,198	5,760	6,040
Selling, General & Admin	3,438	3,296	2,917	2,625	2,624
Depreciation & Amortization Expenses	1,001	1,077	1,077	1,215	1,375
Research & Development	629	616	604	529	465
Other Operating Expenses	372	308	637	937	1,126
Total Operating Expenses	5,440	5,297	5,235	5,306	5,590
Operating Income	1,813	1,546	963	454	450
Interest Income	48	33	26	14	7
Interest Expense	-1,604	-1,388	-1,328	-1,464	-1,426
Other Non-Operating Income (Expense)	110	-24	-51	867	-55
Total Non-Operating Income (Expense)	-1,446	-1,379	-1,353	-583	-1,474
Pretax Income	367	167	-390	-129	-1,024
Provision for Income Taxes	-247	-239	-221	-83	87
Net Income	157	-46	-592	-225	-948
Minority Interest in Earnings	37	26	19	-13	-11
Net Income to Common	157	-46	-592	-225	-948
Shares Outstanding (Basic)	371	368	365	362	359
Shares Outstanding (Diluted)	375	368	365	362	359
Shares Change (YoY)	1.90%	0.85%	0.80%	0.86%	1.10%
EPS (Basic)	0.42	-0.13	-1.62	-0.62	-2.64
EPS (Diluted)	0.42	-0.13	-1.62	-0.62	-2.64
Free Cash Flow	730.75	878	616.61	-946	1,157
Free Cash Flow Growth	-16.77%	42.39%	-	-	43.02%
Free Cash Flow Per Share	1.95	2.39	1.69	-2.61	3.22
Gross Margin	70.65%	71.10%	70.78%	70.90%	71.61%
Operating Margin	17.66%	16.06%	11.00%	5.59%	5.34%
Profit Margin	1.17%	-0.75%	-6.98%	-2.61%	-11.11%
FCF Margin	7.12%	9.12%	7.04%	-11.64%	13.72%
EBITDA	2,693	2,429	1,917	1,848	2,002
EBITDA Margin	26.23%	25.24%	21.89%	22.75%	23.74%
EBIT	1,813	1,546	963	454	450
EBIT Margin	17.66%	16.06%	11.00%	5.59%	5.34%
Effective Tax Rate	-67.30%	-143.11%	56.67%	64.34%	-8.50%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.